Tumor inflammatory microenvironment contribution to survival in resected upstaged adenocarcinomas
-
Published:2024-07
Issue:7
Volume:50
Page:108444
-
ISSN:0748-7983
-
Container-title:European Journal of Surgical Oncology
-
language:en
-
Short-container-title:European Journal of Surgical Oncology
Author:
Bonis Alessandro,
Verzeletti VincenzoORCID,
Lunardi FrancescaORCID,
Lione LuigiORCID,
Cannone GiorgioORCID,
Faccioli Eleonora,
Mammana MarcoORCID,
Nicotra Samuele,
Calabrese Fiorella,
Dell’Amore Andrea,
Rea Federico
Reference29 articles.
1. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial;O'Brien;Lancet Oncol,2022
2. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;Lancet,2021
3. Neoadjuvant PD-1 blockade in resectable lung cancer;Forde;N Engl J Med,2018
4. Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade;Wang;npj Precis Oncol,2022
5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017